Detalhe da pesquisa
1.
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab.
BMC Pediatr
; 22(1): 487, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35965332
2.
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Breast Cancer Res Treat
; 173(3): 585-596, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374681
3.
A Novel GATA1 Variant in the C-Terminal Zinc Finger Compared with the Platelet Phenotype of Patients with A Likely Pathogenic Variant in the N-Terminal Zinc Finger.
Cells
; 11(20)2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291092
4.
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Blood Cancer Discov
; 2(5): 468-483, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568832
5.
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Leukemia
; 35(12): 3509-3525, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34007044
6.
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.
Cancers (Basel)
; 12(2)2020 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019064
7.
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.
PLoS One
; 11(3): e0150507, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26934743
8.
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Leukemia
; 35(12): 3628, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34489554